Propanc Biopharma Inc (PPCB)

$2.87 -5.13 (-64.13%)
Market Cap 155,000.00
Revenue (ttm) 0.00
Net Income (ttm) -1.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 489,547
Avg Vol 2,732
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 94%
Beta 2.78
Analysts Strong Buy
Price Target $12.50

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9882 0780
Fax: 61 3 9882 9969
Address:
302, 6 Butler Street, Camberwell, Australia
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 3:35 PM
$PPCB RSI: 39.29, MACD: -0.0657 Vol: 0.05, MA20: 0.23, MA50: 0.43 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Motorhhead
Motorhhead Feb. 20 at 6:45 PM
$LIMN $PPCB $PLYX $GRAL $IOTR Another excellent set of promotions for the shorts. The excellent short plays just keep coming from this person. It's uncanny! https://stocktwits.com/beppels/message/645412021
0 · Reply
beppels
beppels Feb. 20 at 8:24 AM
$LIMN BEPPELS WL 20.02.: - $LIMN, 0.24 $, 22.6 mln float, offering closed, warrants at 0.29, hit 0.35 just yesterday in pm! ✅ - $PPCB, 0.2 $, 7.56 mln float, penny at lows, had multiple spikes from here to 0.3! ✅ - $PLYX, 2.6 $, 10 mln float, direct lister at lows, grossly oversold, reversal very likely! ✅ Also watch $GRAL, $IOTR, OLOX, CDIO! 👀 🔥 👀
1 · Reply
aafetygod
aafetygod Feb. 20 at 3:04 AM
$PPCB It's a garbage stock, but it's got 300%+ potential eventually. 0.8+.
2 · Reply
WhisperingLions
WhisperingLions Feb. 19 at 6:49 PM
$PPCB LOOKS INTERESTING 🤫🔥🦁💰
1 · Reply
CrowdCap
CrowdCap Feb. 18 at 3:33 PM
$PPCB Propanc Biopharma is an early-stage oncology biotech with binary outcomes. Valuation is driven entirely by clinical progress. Dilution risk remains high without partnerships.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Feb. 17 at 6:34 PM
$PPCB Thanks for sharing your thoughts. We know consistency and capital discipline matter to investors, especially at this stage of development. Preparing for first-in-human work involves both operational and financial planning, and that process continues as part of the development pathway. As milestones are reached, whether related to IP, manufacturing optimization, or regulatory progress, updates will continue to be shared publicly. We appreciate you following the journey.
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Feb. 17 at 6:33 PM
$PPCB Limited compassionate use data has provided early insight into PRP’s potential safety and tolerability profile, with no severe or serious adverse events reported across treated patients. While these observations are preliminary and not predictive of clinical outcomes, they inform how the program is being optimized for intravenous administration ahead of a Phase 1b study. The upcoming clinical phase is designed to systematically evaluate safety, dosing, and biological activity in advanced cancers. Each step builds on the last, reflecting a development model focused on measured progress, transparency, and repeatable execution over time.
1 · Reply
Camwitman89
Camwitman89 Feb. 17 at 3:52 PM
$PPCB very quiet in here, let’s awake this sleeping beast…
1 · Reply
_EmproX
_EmproX Feb. 17 at 2:35 PM
$ENSC $PPCB $TWAV $BFRG <<<><<><
0 · Reply
Latest News on PPCB
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Feb 18, 2026, 8:45 AM EST - 5 days ago

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Feb 5, 2026, 8:45 AM EST - 18 days ago

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Jan 27, 2026, 8:45 AM EST - 27 days ago

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Jan 20, 2026, 8:45 AM EST - 4 weeks ago

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Jan 15, 2026, 8:45 AM EST - 5 weeks ago

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Propanc Biopharma Provides Shareholder Update

Jan 13, 2026, 8:45 AM EST - 5 weeks ago

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 22, 2025, 7:00 AM EST - 2 months ago

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Dec 4, 2025, 8:45 AM EST - 2 months ago

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Dec 1, 2025, 8:45 AM EST - 3 months ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 17, 2025, 8:45 AM EST - 3 months ago

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Nov 10, 2025, 8:45 AM EST - 3 months ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Nov 4, 2025, 7:00 AM EST - 3 months ago

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 5:45 PM EDT - 4 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 8:45 AM EDT - 4 months ago

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Oct 7, 2025, 8:45 AM EDT - 4 months ago

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Sep 17, 2025, 8:45 AM EDT - 5 months ago

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Sep 2, 2025, 9:00 AM EDT - 6 months ago

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 19, 2025, 8:30 AM EDT - 6 months ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

Aug 16, 2025, 12:25 AM EDT - 6 months ago

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

BLSH BUUU KLAR MAGH MIAX NSRX NUTR

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Aug 14, 2025, 11:00 PM EDT - 6 months ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 3:35 PM
$PPCB RSI: 39.29, MACD: -0.0657 Vol: 0.05, MA20: 0.23, MA50: 0.43 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Motorhhead
Motorhhead Feb. 20 at 6:45 PM
$LIMN $PPCB $PLYX $GRAL $IOTR Another excellent set of promotions for the shorts. The excellent short plays just keep coming from this person. It's uncanny! https://stocktwits.com/beppels/message/645412021
0 · Reply
beppels
beppels Feb. 20 at 8:24 AM
$LIMN BEPPELS WL 20.02.: - $LIMN, 0.24 $, 22.6 mln float, offering closed, warrants at 0.29, hit 0.35 just yesterday in pm! ✅ - $PPCB, 0.2 $, 7.56 mln float, penny at lows, had multiple spikes from here to 0.3! ✅ - $PLYX, 2.6 $, 10 mln float, direct lister at lows, grossly oversold, reversal very likely! ✅ Also watch $GRAL, $IOTR, OLOX, CDIO! 👀 🔥 👀
1 · Reply
aafetygod
aafetygod Feb. 20 at 3:04 AM
$PPCB It's a garbage stock, but it's got 300%+ potential eventually. 0.8+.
2 · Reply
WhisperingLions
WhisperingLions Feb. 19 at 6:49 PM
$PPCB LOOKS INTERESTING 🤫🔥🦁💰
1 · Reply
CrowdCap
CrowdCap Feb. 18 at 3:33 PM
$PPCB Propanc Biopharma is an early-stage oncology biotech with binary outcomes. Valuation is driven entirely by clinical progress. Dilution risk remains high without partnerships.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Feb. 17 at 6:34 PM
$PPCB Thanks for sharing your thoughts. We know consistency and capital discipline matter to investors, especially at this stage of development. Preparing for first-in-human work involves both operational and financial planning, and that process continues as part of the development pathway. As milestones are reached, whether related to IP, manufacturing optimization, or regulatory progress, updates will continue to be shared publicly. We appreciate you following the journey.
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Feb. 17 at 6:33 PM
$PPCB Limited compassionate use data has provided early insight into PRP’s potential safety and tolerability profile, with no severe or serious adverse events reported across treated patients. While these observations are preliminary and not predictive of clinical outcomes, they inform how the program is being optimized for intravenous administration ahead of a Phase 1b study. The upcoming clinical phase is designed to systematically evaluate safety, dosing, and biological activity in advanced cancers. Each step builds on the last, reflecting a development model focused on measured progress, transparency, and repeatable execution over time.
1 · Reply
Camwitman89
Camwitman89 Feb. 17 at 3:52 PM
$PPCB very quiet in here, let’s awake this sleeping beast…
1 · Reply
_EmproX
_EmproX Feb. 17 at 2:35 PM
$ENSC $PPCB $TWAV $BFRG <<<><<><
0 · Reply
_EmproX
_EmproX Feb. 17 at 2:19 PM
$RMSG $PPCB $CPHI $RYI ||~~||
0 · Reply
Trapboycesar
Trapboycesar Feb. 17 at 2:09 PM
$GVH easy money. Taking profits to $PPCB
0 · Reply
Trapboycesar
Trapboycesar Feb. 17 at 1:42 PM
$PPCB up next
0 · Reply
MihawkSwings
MihawkSwings Feb. 17 at 1:22 PM
OLB 💎 Starting to breakout here. keep an eye! Massive gap up potential on ticker OLB. With 0 shares to borrow this can squeeze up fast. Make sure not to miss out on this opportunity bulls. $GXAI $NCI $PPCB $BRTX //.m
0 · Reply
beppels
beppels Feb. 17 at 8:17 AM
$SSKN BEPPELS WL 17.02.: - $SSKN, 0.3 $, 4.14 mln float, 1.8 mln mc, delisting Thursday, will see a final run today or never! ✅ - $PPCB, 0.24 $, 6.8 mln float, already had two spikes to 0.3, next one could take it higher, clean Penny! ✅ - $BRTX, 0.28 $, 22.8 mln float, offering closed Friday at 0.35 $!✅ - $ISPC, 0.3 $, 9.77 mln float, 0.64 $ cash per share, hit 0.37 $ just Friday, rock bottom around 0.3!✅ - $FCUV, 5 $, 400 K float, 5.5 $ cash per share, top bottom play! ✅ Also watch OLB, ERNA, PRFX! 👀 🔥 👀
0 · Reply
Kesiya
Kesiya Feb. 17 at 3:03 AM
$PPCB Exit zone!
0 · Reply
WhisperingLions
WhisperingLions Feb. 16 at 1:12 AM
$PPCB HOLDING 🦁🔥
0 · Reply
topstockalerts
topstockalerts Feb. 14 at 1:18 AM
After Hours Top Gainers PT2 $FRGT $KZIA $GLXG $OLB $PPCB
0 · Reply
EmproX
EmproX Feb. 14 at 12:47 AM
+hey guys ticker IBG could set up for a massive squeeze next week. .SMX ran on 1 mil float IBG has 580k float, put IBG on your watchlist. IBG next week big squeeze watch merger news took a big position!! $FGNX $EPSM $OLB $PPCB <~
0 · Reply
MihawkSwings
MihawkSwings Feb. 13 at 10:39 PM
Looks like everyone is moving to OLB🚨🚨 Ticker OLB is the next massive squeezer about to take place. OLB 0 shares to borrow, shorts are about to get squeezed.🚨🚨 $RIME $FRGT $NCI $PPCB watching.
0 · Reply
Universelaw
Universelaw Feb. 13 at 10:16 PM
$PPCB
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Feb. 13 at 10:06 PM
$PPCB Hi @RickCaster, Propanc is an oncology-focused biotechnology company advancing PRP through a defined scientific and regulatory pathway while continuing to expand and protect its global intellectual property portfolio. Our priority is advancing PRP toward the clinic and protecting the platform globally. Visibility tends to follow execution in biotech. We appreciate your engagement and interest in the Company.
1 · Reply